FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed is an isolated fusion protein for inhibiting or reducing high serine protease activity. Also disclosed is a method of inhibiting or reducing high expression or serine protease activity.
EFFECT: present invention can find further application in therapy of various diseases, particularly emphysema, psoriasis and others.
15 cl, 17 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION SERPINE POLYPEPTIDES AND METHODS FOR THEIR APPLICATION | 2012 |
|
RU2642310C2 |
| FUSION POLYPEPTIDE CONTAINING WAP DOMAIN AND THEIR APPLICATION METHODS | 2012 |
|
RU2639526C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| POLYPEPTIDES | 2011 |
|
RU2577964C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
